A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma

British Journal of Cancer

Volumn 84, Issue 4, 2001, Pages 465-469

  Blackhall, F H ^a   Ranson, M ^a   Radford, J A ^a   Hancock, B W ^b   Soukop, M ^c   McGown, A T ^d   Robbins, A ^e   Halbert, G ^f  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Bryostatin 1; Non Hodgkin's lymphoma; Protein kinase C inhibitors

Indexed keywords

BRYOSTATIN 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; MYALGIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LACTONES; LYMPHOMA, NON-HODGKIN; MACROLIDES; MALE; MIDDLE AGED; PHLEBITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0035099740     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1624     Document Type: Article

References (36)

1. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografls
2. Sensitisation of human cervical carcinoma cells to cisdiamminediachloroplatinum(II) by bryostatin 1
3. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity
4. The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus
5. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML
6. The determination of the number of patients required in a preliminary and a follow up trial of a new chemotherapeutic agent
7. Treatment of patients with metastatic melanoma with bryostatin 1 - A phase II study
8. Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: A 31P magnetic resonance spectrospic study
9. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumour cell lines: In vitro versus in vivo activity
10. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
11. A phase I trial of weekly sequential bryostatin-1 and paclitaxel in patients with advanced solid tumours
12. High performance liquid chromatographic assay for the novel antitumour drug, bryostatin-1, incorporating a serum extraction technique
13. The in vivo effect of bryostatin 1 on paclitaxel-induced tumour growth mitotic entry, and blood flow
14. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma
15. Antineoplastic bryostatins am multipotential stimulators of human haematopoietic progenitor cells
16. Bryostatin 1 - Tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro
17. Reporting results of cancer treatment
18. Differential effects of bryostatin 1 on human non-Hodgkin's lymphoma cell lines
19. Successful treatment of human Waldenstrom's macroglobulinaemia with combination biological and chemotherapy agents
20. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma
21. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukaemia cell line (WSU-CLL): Association with increased ratios of dCK/5-NT and Bax/Bcl-2
22. Studies and perspectives of protein kinase C
23. Isolation and structure of bryostatin 1
24. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor α induction in vivo
25. A phase I study of intravenous bryostatin 1 in patients with advanced cancer
26. A phase II study of bryostatin 1 metastic malignant melanoma
27. Phase I study of bryostatin-1 (NSC 339555) and cisplatin in advanced malignancies
28. Immunomodulation in patients receiving intravenous bryostatin 1 in a phase 1 clinical study: Comparison with effects of bryostatin 1 on lymphocyte function in vitro
29. The action of bryostatin on normal human haematopoietic progenitors is mediated by accessory cell release of growth factors
30. Updated Kiel Classification for lymphomas
31. Modulation of bryostatin 1 muscle toxicity by nifedipine: Effects on muscle metabolism and oxygen supply
32. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
33. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
34. A Phase I trial of bryostatin 1 in children with refractory solid tumours: A Pediatric Oncology Group study
35. Matrix metalloproteinase inhibitors